MinorEnrollment closed, study ongoingShow 4 more changesShow less
Trial sites reduced: 123 → 120 locations
Enrollment target: estimated 600 to confirmed 601
Eligibility criteria expanded, about 12 words
Secondary endpoints: 25 to 23
MinorRe-verified, no change to tracked fieldsv21
MinorSite details revised at 1 of 123 sitesv20
MinorStudy sites: 122 to 123v19
MinorRe-verified, no change to tracked fieldsv18
Show 16 earlier versionsHide 16 earlier versions
MinorStudy sites: 123 to 122v17
MinorStudy sites: 122 to 123v16
MinorStudy sites: 123 to 122v15
MinorSite details revised at 8 of 123 sitesv14
MinorSite details revised at 5 of 123 sitesv13
MinorSite details revised at 7 of 123 sitesv12
MinorSite details revised at 4 of 123 sitesv11
MinorSite details revised at 7 of 123 sitesv10
MinorEligibility criteria expanded, about 20 words
Secondary endpoints: 23 to 25
Site details revised at 12 of 123 sites
v9
MinorSite details revised at 6 of 123 sitesv8
MinorSite details revised at 15 of 123 sitesv7
MinorSite details revised at 19 of 123 sitesv6
MinorSite details revised at 24 of 123 sitesv5
MinorSite details revised at 2 of 123 sitesv4
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 0 to 123
Start date changed from estimate of Mar 6, 2025 to Mar 10, 2025
v3
MinorStudy Status, Conditions, Referencesv2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments.
The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.